Atossa Therapeutics, Inc.ATOSNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+6.9%
5Y CAGR+22.8%
Year-over-Year Change
Research and development spending
3Y CAGR
+6.9%/yr
vs +37.6%/yr prior
5Y CAGR
+22.8%/yr
Recent deceleration
Acceleration
-30.7pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.8x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $18.43M | +30.6% |
| 2024 | $14.12M | -18.6% |
| 2023 | $17.33M | +14.9% |
| 2022 | $15.08M | +63.8% |
| 2021 | $9.21M | +39.4% |
| 2020 | $6.61M | -7.3% |
| 2019 | $7.13M | +69.4% |
| 2018 | $4.21M | +80.8% |
| 2017 | $2.33M | +202.2% |
| 2016 | $770427.00 | - |